Risk Factors for and Effects of Persistent and Severe Hypophosphatemia Following Ferric Carboxymaltose

Journal of Clinical Endocrinology and Metabolism

Volumn 107, Issue 4, 2022, Pages 1009-1019

  Schaefer, Benedikt ^a   Zoller, Heinz ^a   Wolf, Myles ^b  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

alkaline phosphatase; clinical trials; FGF23; hypophosphatemia; intravenous iron; PTH

Indexed keywords

ALKALINE PHOSPHATASE; CALCITRIOL; CALCIUM ION; FERRIC CARBOXYMALTOSE; FIBROBLAST GROWTH FACTOR 23; INTACT FIBROBLAST GROWTH FACTOR 23; IRON ISOMALTOSE; N TERMINAL PROCOLLAGEN 1 PEPTIDE; PARATHYROID HORMONE; PHOSPHATE; PROCOLLAGEN; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; CALCIUM; DISACCHARIDE; FERRIC ION; IRON; MALTOSE; MINERAL;

ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; CALCIUM BLOOD LEVEL; CONTROLLED STUDY; DEMOGRAPHY; DISEASE ASSOCIATION; DRUG SAFETY; FEMALE; HUMAN; HYPOPHOSPHATEMIA; IRON DEFICIENCY ANEMIA; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; PARATHYROID HORMONE BLOOD LEVEL; PERSISTENT HYPOPHOSPHATEMIA; PHOSPHATE BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SEVERE HYPOPHOSPHATEMIA; UNITED STATES; COMPLICATION; FAMILIAL HYPOPHOSPHATEMIC RICKETS; OSTEOMALACIA;

ALKALINE PHOSPHATASE; ANEMIA, IRON-DEFICIENCY; BIOMARKERS; CALCIUM; DISACCHARIDES; FAMILIAL HYPOPHOSPHATEMIC RICKETS; FEMALE; FERRIC COMPOUNDS; HUMANS; HYPOPHOSPHATEMIA; IRON; MALE; MALTOSE; MINERALS; OSTEOMALACIA; PARATHYROID HORMONE; RISK FACTORS;

EID: 85127871305     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/clinem/dgab852     Document Type: Article

References (31)

1. Camaschella C. Iron-deficiency anemia. N Engl J Med. 2015;372(19):1832-1843.
2. Pasricha SR, Tye-Din J, Muckenthaler MU, Swinkels DW. Iron deficiency. Lancet. 2021;397(10270):233-248.
3. Onken JE, Bregman DB, Harrington RA, et al. A multicenter, randomized, active-controlled study to investigate the efficacy and safety of intravenous ferric carboxymaltose in patients with iron deficiency anemia. Transfusion. 2014;54(2):306-315.
4. Stein J, Walper A, Klemm W, Farrag K, Aksan A, Dignass A. Safety and efficacy of intravenous iron isomaltoside for correction of anaemia in patients with inflammatory bowel disease in everyday clinical practice. Scand J Gastroenterol. 2018;53(9):1059-1065.
5. Blumenstein I, Shanbhag S, Langguth P, Kalra PA, Zoller H, Lim W. Newer formulations of intravenous iron: a review of their chemistry and key safety aspects-hypersensitivity, hypophosphatemia, and cardiovascular safety. Expert Opin Drug Saf. 2021;20(7):757-769.
6. Bhandari S, Kalra PA, Berkowitz M, Belo D, Thomsen LL, Wolf M. Safety and efficacy of iron isomaltoside 1000/ferric derisomaltose versus iron sucrose in patients with chronic kidney disease: the FERWON-NEPHRO randomized, open-label, comparative trial. Nephrol Dial Transplant. 2021;36(1):111-120.
7. Pollock RF, Muduma G. A systematic literature review and indirect comparison of iron isomaltoside and ferric carboxymaltose in iron deficiency anemia after failure or intolerance of oral iron treatment. Expert Rev Hematol. 2019;12(2):129-136.
8. Auerbach M, Henry D, Derman RJ, Achebe MM, Thomsen LL, Glaspy J. A prospective, multi-center, randomized comparison of iron isomaltoside 1000 versus iron sucrose in patients with iron deficiency anemia; the FERWON-IDA trial. Am J Hematol. 2019;94(9):1007-1014.
9. Derman R, Roman E, Modiano MR, Achebe MM, Thomsen LL, Auerbach M. A randomized trial of iron isomaltoside versus iron sucrose in patients with iron deficiency anemia. Am J Hematol. 2017;92(3):286-291.
10. Onken JE, Bregman DB, Harrington RA, et al. Ferric carboxymaltose in patients with iron-deficiency anemia and impaired renal function: the REPAIR-IDA trial. Nephrol Dial Transplant. 2014;29(4):833-842.
11. Schaefer B, Tobiasch M, Viveiros A, et al. Hypophosphataemia after treatment of iron deficiency with intravenous ferric carboxymaltose or iron isomaltoside-a systematic review and meta-analysis. Br J Clin Pharmacol. 2020;87(5):2256-2273.
12. Wolf M, Rubin J, Achebe M, et al. Effects of iron isomaltoside vs ferric carboxymaltose on hypophosphatemia in irondeficiency anemia: two randomized clinical trials. JAMA. 2020;323(5):432-443.
13. Detlie TE, Lindstrom JC, Jahnsen ME, et al. Incidence of hypophosphatemia in patients with inflammatory bowel disease treated with ferric carboxymaltose or iron isomaltoside. Aliment Pharmacol Ther. 2019;50(4):397-406.
14. Wolf M, Koch TA, Bregman DB. Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women. J Bone Miner Res. 2013;28(8):1793-1803.
15. Edmonston D, Wolf M. FGF23 at the crossroads of phosphate, iron economy and erythropoiesis. Nat Rev Nephrol. 2020;16(1):7-19.
16. Schaefer B, Meindl E, Wagner S, Tilg H, Zoller H. Intravenous iron supplementation therapy. Mol Aspects Med. 2020;75:100862.
17. InjectaferR (ferric carboxymaltose). Prescribing Information. Vifor International, Inc.; 2020.
18. MonoferricR (ferric derisomaltose). Prescribing Information. Pharmacosmos A/S; 2020.
19. Wolf M, Chertow GM, Macdougall IC, Kaper R, Krop J, Strauss W. Randomized trial of intravenous iron-induced hypophosphatemia. JCI Insight. 2018;3(23):e124486.
20. Chotiyarnwong P, McCloskey EV. Pathogenesis of glucocorticoid-induced osteoporosis and options for treatment. Nat Rev Endocrinol. 2020;16(8):437-447.
21. Peach H, Compston JE, Vedi S, Horton LW. Value of plasma calcium, phosphate, and alkaline phosphatase measurements in the diagnosis of histological osteomalacia. J Clin Pathol. 1982;35(6):625-630.
22. Schaefer B, Tobiasch M, Wagner S, et al. Hypophosphatemia after intravenous iron therapy: comprehensive review of clinical findings and recommendations for management. Bone. 2021;154:116202.
23. Klein K, Asaad S, Econs M, Rubin JE. Severe FGF23-based hypophosphataemic osteomalacia due to ferric carboxymaltose administration. BMJ Case Rep. 2018;2018:bcr2017222851.
24. FerinjectR (ferric carboxymaltose). Summary of Product Characteristics. Vifor France; 2020.
25. FerinjectR (ferric carboxymaltose). Prescribing Information (Brazil). Vifor (International) Inc.; 2020.
26. Frazier R, Hodakowski A, Cai X, et al. Effects of ferric carboxymaltose on markers of mineral and bone metabolism: A single-center prospective observational study of women with iron deficiency. Bone. 2020;141:115559.
27. Schaefer B, Wurtinger P, Finkenstedt A, et al. Choice of high-dose intravenous iron preparation determines hypophosphatemia risk. PLoS One. 2016;11(12):e0167146.
28. Rosano G, Schiefke I, Gohring U-M, Fabien V, Bonassi S, Stein J. A pooled analysis of serum phosphate measurements and potential hypophosphataemia events in 45 interventional trials with ferric carboxymaltose. J Clin Med. 2020;9(11):3587.
29. Zoller H, Schaefer B, Glodny B. Iron-induced hypophosphatemia: an emerging complication. Curr Opin Nephrol Hypertens. 2017;26(4):266-275.
30. Sangros Sahun MJ, Goni Gironés E, Camarero Salazar A, Estébanez Estébanez C, Lozano Martinez ME. Symptomatic hypophosphataemic osteomalacia secondary to the treatment with iron carboxymaltose detected in bone scintigraphy. Rev Esp Med Nucl Imagen Mol. 2016;35(6): 391-393.
31. Schaefer B, Glodny B, Zoller H. Blood and bone loser. Gastroenterology. 2017;152(6):e5-e6.